Mason Morfit

ValueAct to Cut Stake in Valeant Pharmaceuticals (VRX); Vacates Board Seat

Mason Morfit, the chief executive officer of ValueAct Capital resigned as director of the board of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to be able to reduce the position of the activist hedge in the...

Recent posts

Popular categories